Advertisement

Safety and efficacy of anticoagulant monotherapy in atrial fibrillation and stable coronary artery disease: A systematic review and meta-analysis

      Highlights

      • OAC monotherapy might have a lower incidence of major bleeding in patients with AF and stable CAD.
      • OAC monotherapy does not confer a higher risk of major adverse cardiovascular events, mortality or stroke.
      • Larger scale studies are needed to validate our findings.

      Abstract

      Background

      Adjunctive use of oral anticoagulant (OAC) and antiplatelet therapy (APT) in patients with stable coronary artery disease (CAD) and nonvalvular atrial fibrillation (AF) is a challenge of daily practice.

      Methods

      A comprehensive literature search of databases was performed to identify studies comparing the safety and efficacy of OAC monotherapy and combined therapy (OAC plus single (S) APT). Events including major adverse cardiovascular events (MACE), all-cause mortality, stroke and major bleeding were analyzed.

      Results

      Seven articles comprising 11,070 subjects were identified. Combined therapy was associated with a significantly higher risk of major bleeding (pooled hazard ratio (HR) of 1.62, 95% CI 1.40–1.86, p=<0.0001) compared to the OAC monotherapy. There was no significant difference between the two comparison arms in terms of MACE (HR 1.14; 95% CI 0.97–1.34, p = 0.11), stroke (HR 1.05; 95% CI 0.77–1.43, p = 0.78) and all-cause mortality (HR 1.15; 95% CI 0.94–1.40, p = 0.16). Stratified analysis by inclusion of only patients with coronary stents attenuated the safety effect of monotherapy. Subgroup analysis based on the study design, type of OAC, major bleeding criteria and APT revealed findings consistent with the pooled HR. The combined therapy group had a 19% and 38% higher risk of MACE in studies with a history of MI (p = 0.03) and with the use of rivaroxaban (p = 0.02), respectively.

      Conclusion

      OAC monotherapy might have a lower incidence of major bleeding events with no higher overall risk of MACE, ischemic stroke and all-cause mortality compared to the combined therapy group.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Leon M.B.
        • Baim D.S.
        • Popma J.J.
        • et al.
        A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting.
        N Engl J Med. 1998; 339: 1665-1671
        • van Walraven C.
        • Hart R.G.
        • Singer D.E.
        • et al.
        Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis.
        JAMA. 2002; 288: 2441-2448https://doi.org/10.1001/jama.288.19.2441
        • Kralev S.
        • Schneider K.
        • Lang S.
        • et al.
        Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography.
        PLoS ONE. 2011; 6: e24964
        • van Rein N.
        • Heide-Jørgensen U.
        • Lijfering W.M.
        • Dekkers O.M.
        • Sørensen H.T.
        • Cannegieter S.C
        Major bleeding rates in atrial fibrillation patients on single, dual, or triple antithrombotic therapy.
        Circulation. 2019; 139: 775-786
        • Camm A.J.
        • Lip G.Y.
        • De Caterina R.
        • Bax J.J.
        • ESC Committee for Practice Guidelines (CPG)
        2012 Focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation developed with the special contribution of the European Heart Rhythm Association.
        Eur Heart J. 2012; 33: 2719-2747
        • Angiolillo D.J.
        • Goodman S.G.
        • Bhatt D.L.
        • et al.
        Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: a North American perspective–2018 update.
        Circulation. 2018; 138: 527-536
        • Matsumura-Nakano Y.
        • Shizuta S.
        • Komasa A.
        • et al.
        Open-label randomized trial comparing oral anticoagulation with and without single antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease beyond 1 year after coronary stent implantation: OAC-ALONE study.
        Circulation. 2019; 139: 604-616
        • Yasuda S.
        • Kaikita K.
        • Akao M.
        • Matsui K.
        • et al.
        Antithrombotic therapy for atrial fibrillation with stable coronary disease.
        N Engl J Med. 2019; 381: 1103-1113
        • Lamberts M.
        • Gislason G.H.
        • Lip G.Y.
        • et al.
        Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study.
        Circulation. 2014; 129: 1577-1585
        • Patti G.
        • Pecen L.
        • Lucerna M.
        • et al.
        Outcomes of anticoagulated patients with atrial fibrillation treated with or without antiplatelet therapy - a pooled analysis from the PREFER in AF and PREFER in AF PROLONGATON registries.
        Int J Cardiol. 2018; 270: 160-166
        • Fischer Q.
        • Georges J.L.
        • Le Feuvre C.
        • et al.
        Optimal long-term antithrombotic treatment of patients with stable coronary artery disease and atrial fibrillation: "OLTAT registry.
        Int J Cardiol. 2018; 264: 64-69
        • Hamon M.
        • Lemesle G.
        • Tricot O.
        • et al.
        Incidence, source, determinants, and prognostic impact of major bleeding in outpatients with stable coronary artery disease.
        J Am Coll Cardiol. 2014; 64: 1430-1436
        • Lemesle G.
        • Ducrocq G.
        • Elbez Y.
        • et al.
        Vitamin K antagonists with or without long-term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: association with ischemic and bleeding events.
        Clin Cardiol. 2017; 40: 932-939